Product Information

ERYTHROMYCIN 400 MG/5 ML SUSP is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $1.5711 per ML under NDC 75834029401. Its NADAC has been published 185 times since May 10, 2023.

FDA first approved this application on Nov 21, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

ERYTHROMYCIN 400 MG/5 ML SUSP

Erythromycin Ethylsuccinate
$1.5711per ML

Strength

400 mg/5mL

NDC

75834029401

Classification

Generic

Dosage Form

SUSPENSION

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

ERYTHROMYCIN ETHYLSUCCINATE

Approval Type

Generic (ANDA)

FDA Application

ANDA216212

FDA Approved

11/21/2022

TE Code

AB

On Market Since

2/1/2023

Pharmacological Classes

Decreased Sebaceous Gland Activity
Macrolide Antimicrobial
Macrolide
Macrolides

Price Statistics

The NADAC for ERYTHROMYCIN 400 MG/5 ML SUSP has been published 185 times since May 10, 2023, and over the history we have for it it has declined 41.5%. The table below summarizes its recorded NADAC range and movement.

Current price$1.5711 per ML
All-time high$2.7783 (Apr 10, 2024)
All-time low$1.5711 (Nov 18, 2026)
52-week high$2.0426
52-week low$1.5711
Median price$1.9781
Average price$2.1402
Largest weekly change-20.3% (Apr 17, 2024)
Weeks tracked185
Tracking sinceMay 10, 2023

Price History

1W

-5.9%

1M

-9.9%

3M

-8.9%

6M

-12.0%

1Y

-26.8%

3Y

-41.5%

5Y

N/A

All

-41.5%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of ERYTHROMYCIN 400 MG/5 ML SUSP?

The current National Average Drug Acquisition Cost (NADAC) for ERYTHROMYCIN 400 MG/5 ML SUSP, manufactured by Nivagen Pharmaceuticals Inc., is $1.5711 per ML (NDC 75834029401), effective Nov 18, 2026.

How has the price of ERYTHROMYCIN 400 MG/5 ML SUSP changed over time?

Over the history we have for it, the NADAC for ERYTHROMYCIN 400 MG/5 ML SUSP has declined 41.5%. It has been tracked across 185 weekly CMS publications since May 10, 2023.

What are the highest and lowest recorded NADAC prices for ERYTHROMYCIN 400 MG/5 ML SUSP?

Since May 10, 2023, the NADAC for ERYTHROMYCIN 400 MG/5 ML SUSP has ranged from a low of $1.5711 (Nov 18, 2026) to a high of $2.7783 (Apr 10, 2024), with a median of $1.9781 per ML.

Are there cheaper alternatives to ERYTHROMYCIN 400 MG/5 ML SUSP?

3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ERYTHROMYCIN 400 MG/5 ML SUSP in a comparable dosage form, but none are currently priced below it.

Who manufactures ERYTHROMYCIN 400 MG/5 ML SUSP?

ERYTHROMYCIN 400 MG/5 ML SUSP (NDC 75834029401) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.